Lessons from DAWN: Implementing effective insulin therapy

Internet Journal of Advanced Nursing Practice

Volumn 10, Issue 2, 2009, Pages

  Funnell, Martha M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Barriers; DAWN; Diabetes; Insulin; Nurse; Type 2

Indexed keywords

EID: 77950927134     PISSN: None     EISSN: 15236064     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Centers for Disease Control and Prevention. National diabetes fact sheet, 2007
2. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008; 31(3):596-615
3. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care. 2008; 31(Suppl 1):S12-S54
4. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68
5. U.K. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44(11):1249-58
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 31(1):173-5
7. Skovlund SE, Peyrot M,on behalf of the DAWN International Advisory Panel. The Diabetes Attitudes, Wishes, and Needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectr. 2005; 18(3):136-42
8. Funnell MM. The Diabetes Attitudes, Wishes, and Needs (DAWN) study. Clin Diabetes. 2006; 24(4):154-5
9. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005; 22(10):1379-85
10. Siminerio LM, Funnell MM, Peyrot M, Rubin RR. US nurses' perceptions of their role in diabetes care: results of the cross-national Diabetes Attitudes Wishes and Needs (DAWN) study. Diabetes Educ. 2007; 33(1):152-62
11. Peyrot M, Rubin RR, Siminerio LM. Physician and nurse use of psychosocial strategies in diabetes care: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006; 29(6):1256-62
12. Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006; 29(6):1249-55
13. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003; 9(3):213-7
14. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007; 22(4):453-8
15. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27(7):1535-40
16. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28(11):2673-9
17. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008; 62(6):860-8
18. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005; 28(10):2543-5
19. Funnell MM, Kruger DF, Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ. 2004; 30(2):274-80
20. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005; 27(Suppl B):S89-S100
21. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006; 28(10):1712-25; discussion, 1710-1
22. Gerich JE Novel insulins: expanding options in diabetes management. Am J Med. 2002; 113(4):308-316
23. Heinemann L. Overcoming obstacles: new management options. Eur J Endocrinol. 2004; 151(Suppl 2):T23-7; discussion, T29-30
24. Owens DR, Bolli GB. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008;10(5):333-49
25. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997; 20(3):292-8
26. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26(11):3080-6
27. Dornhorst A, Luddeke HJ, Koenen C, Merilainen M, King A, Robinson A, Sreenan S. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab. 2008; 10(1):75-81
28. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008; 25(4):442-9
29. Rosenstock J, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a metaanalysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28:950-5
30. Dailey, G., & Strange, P. (2008). Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care, 14(1), 25-30.
31. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008; 51(3):408-16
32. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005; 22(6):749-55
33. Fajardo Montanana C, Hernandez Herrero C, Rivas Fernadez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE( BMI clinical trial. Diabet Med. 2008; 25:916-23
34. Bode B. Is weight gain an unavoidable consequence of insulin therapy? Internet J Int Med. 2007 (6):2. Available from URL: http://www.ispub.com/ostia/index.php?xmlPrinter=true&xmlFilePath=journals/ijim/vol6n2/weight.xml.
35. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005; 7(1):56-64
36. Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007; 9(6):902-13
37. Polonsky WH, Earles J, Smith S, Pease DJ, Macmillan M, Christensen R, Taylor T, Dickert J, Jackson RA. Integrating medical management with diabetes self-management training: a randomized control trial of the Diabetes Outpatient Intensive Treatment program. Diabetes Care. 2003; 26(11):3048-53
38. Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care. 2001; 24(10):1821-33
39. Meuelpas MA, Braspenning, JC, de Grauw WJ, Lucas AE, Harms L, Akkermans RP, Grol RP. Logistic support service improves processes and outcomes of diabetes care in general practice. Fam Prac. 2007; 24(1):1-2
40. Siminerio LM. Implementing diabetes self-management training programs: breaking through the barriers in primary care. Endocr Pract. 2006; 12(Suppl 1):124-30
41. Siminerio LM, Piatt GA, Emerson S, Ruppert K, Saul M, Solano F et al. Deploying the chronic care model to implement and sustain diabetes self-management and training programs. Diabetes Educ. 2006; 32(2):253-60
42. Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D et al. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv. 2001; 27(2):63-80
43. Krein SL, Funnell MM, Piette JD. Economics of diabetes mellitus. Nurs Clin North Am. 2006; 41(4):499-511,v-vi
44. Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin, 2008; 24(1):11-20
45. Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006; 29(1):1-8